Literature DB >> 16474115

Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus.

Randall J Cohrs1, Donald H Gilden, Yasuyuki Gomi, Koichi Yamanishi, Jeffrey I Cohen.   

Abstract

The attenuated Oka vaccine (V-Oka) strain of varicella-zoster virus (VZV) effectively reduces disease produced by primary infection and virus reactivation. V-Oka was developed by propagation of the Oka parental (P-Oka) strain of VZV in guinea pig and human embryo fibroblasts. Complete DNA sequencing of both viruses has revealed 63 sites that differ between P-Oka and V-Oka, 37 of which are located within 21 unique open reading frames (ORFs). Of the ORFs that differ, ORF 62 contains the greatest number (10) of mutated sites. ORF 62 encodes IE 62, the major immediate-early transactivator of virus genes, and is essential for lytic virus replication. To determine whether a disproportionate number of mutations in ORF 62 might account for virus attenuation, we compared the global pattern of V-Oka gene expression to that of P-Oka. Transcription of ORFs 62, 65, 66, and 67 was suppressed, whereas ORF 41 was elevated in V-Oka-infected cells compared to P-Oka-infected cells (P < 0.01; z test). Suppression of ORF 62, 65, and 66 transcription was confirmed by quantitative dot blot and Western blot analyses. Transient-transfection assays to determine whether mutations within V-Oka-derived IE 62 affected its ability to transactivate VZV gene promoters revealed similar IE 62 transactivation of VZV gene 20, 21, 28, 29, 65, and 66 promoters in both P-Oka and V-Oka. Together, our results indicate that mutations in V-Oka IE 62 alone are unlikely to account for vaccine virus attenuation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474115      PMCID: PMC1395396          DOI: 10.1128/JVI.80.5.2076-2082.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs.

Authors:  C Grose
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

3.  Intracellular transport of the glycoproteins gE and gI of the varicella-zoster virus. gE accelerates the maturation of gI and determines its accumulation in the trans-Golgi network.

Authors:  A Alconada; U Bauer; L Baudoux; J Piette; B Hoflack
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

4.  Varicella-zoster virus glycoproteins E and I expressed in insect cells form a heterodimer that requires the N-terminal domain of glycoprotein I.

Authors:  H Kimura; S E Straus; R K Williams
Journal:  Virology       Date:  1997-07-07       Impact factor: 3.616

5.  Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin.

Authors:  D C Johnson; V Feenstra
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

6.  Complex formation facilitates endocytosis of the varicella-zoster virus gE:gI Fc receptor.

Authors:  J K Olson; C Grose
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Varicella-zoster virus glycoprotein I is essential for growth of virus in Vero cells.

Authors:  J I Cohen; H Nguyen
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA.

Authors:  M Moriuchi; H Moriuchi; S E Straus; J I Cohen
Journal:  Virology       Date:  1994-04       Impact factor: 3.616

Review 9.  Effectiveness of live varicella vaccine.

Authors:  Michiaki Takahashi
Journal:  Expert Opin Biol Ther       Date:  2004-02       Impact factor: 4.388

10.  The varicella-zoster virus ORF66 protein induces kinase activity and is dispensable for viral replication.

Authors:  T C Heineman; K Seidel; J I Cohen
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  16 in total

1.  Development and evaluation of SYBR Green-I based quantitative PCR assays for herpes simplex virus type 1 whole transcriptome analysis.

Authors:  Cathryn E Garvey; Chris L McGowin; Timothy P Foster
Journal:  J Virol Methods       Date:  2014-03-04       Impact factor: 2.014

2.  Prevalence and abundance of latently transcribed varicella-zoster virus genes in human ganglia.

Authors:  Randall J Cohrs; Donald H Gilden
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture.

Authors:  Aruna P N Ambagala; Tammy Krogmann; Jing Qin; Lesley Pesnicak; Jeffrey I Cohen
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

4.  Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts.

Authors:  Mark L Quinlivan; Anne A Gershon; Mahmoud M Al Bassam; Sharon P Steinberg; Philip LaRussa; Richard A Nichols; Judith Breuer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

5.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

6.  The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.

Authors:  Geoffrey A Peters; Shaun D Tyler; John E Carpenter; Wallen Jackson; Yasuko Mori; Ann M Arvin; Charles Grose
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

7.  Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays.

Authors:  Esther Grinfeld; Alan Ross; Thorsten Forster; Peter Ghazal; Peter G E Kennedy
Journal:  Virus Genes       Date:  2008-11-27       Impact factor: 2.332

8.  Infectivity of herpes simplex virus type-1 (HSV-1) amplicon vectors in dendritic cells is determined by the helper virus strain used for packaging.

Authors:  Kathlyn Santos; Christine M Sanfilippo; Wade C Narrow; Ann E Casey; Sol M Rodriguez-Colon; Michael P McDermott; Howard J Federoff; William J Bowers; Stephen Dewhurst
Journal:  J Virol Methods       Date:  2007-07-02       Impact factor: 2.014

9.  Analysis of IE62 mutations found in Varicella-Zoster virus vaccine strains for transactivation activity.

Authors:  Hyemin Ko; Gwang Myeong Lee; Ok Sarah Shin; Moon Jung Song; Chan Hee Lee; Young Eui Kim; Jin-Hyun Ahn
Journal:  J Microbiol       Date:  2018-06-01       Impact factor: 2.902

10.  Prevention of shingles: safety and efficacy of live zoster vaccine.

Authors:  Dianna Quan; Randall J Cohrs; Ravi Mahalingam; Donald H Gilden
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.